Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1.


Journal

Nature chemical biology
ISSN: 1552-4469
Titre abrégé: Nat Chem Biol
Pays: United States
ID NLM: 101231976

Informations de publication

Date de publication:
08 2022
Historique:
received: 15 09 2021
accepted: 13 04 2022
pubmed: 1 6 2022
medline: 3 8 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Given the promising clinical value of allosteric modulators of G protein-coupled-receptors (GPCRs), mechanistic understanding of how these modulators alter GPCR function is of significance. Here, we report the crystallographic and cryo-electron microscopy structures of the cannabinoid receptor CB1 bound to the positive allosteric modulator (PAM) ZCZ011. These structures show that ZCZ011 binds to an extrahelical site in the transmembrane 2 (TM2)-TM3-TM4 surface. Through (un)biased molecular dynamics simulations and mutagenesis experiments, we show that TM2 rearrangement is critical for the propagation of allosteric signals. ZCZ011 exerts a PAM effect by promoting TM2 rearrangement in favor of receptor activation and increasing the population of receptors that adopt an active conformation. In contrast, ORG27569, a negative allosteric modulator (NAM) of CB1, also binds to the TM2-TM3-TM4 surface and exerts a NAM effect by impeding the TM2 rearrangement. Our findings fill a gap in the understanding of CB1 allosteric regulation and could guide the rational design of CB1 allosteric modulators.

Identifiants

pubmed: 35637350
doi: 10.1038/s41589-022-01038-y
pii: 10.1038/s41589-022-01038-y
doi:

Substances chimiques

Receptor, Cannabinoid, CB1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-840

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).
pubmed: 29075003 pmcid: 6882681 doi: 10.1038/nrd.2017.178
Slosky, L. M., Caron, M. G. & Barak, L. S. Biased allosteric modulators: new frontiers in GPCR drug discovery. Trends Pharmacol. Sci. 42, 283–299 (2021).
pubmed: 33581873 doi: 10.1016/j.tips.2020.12.005
Bueno, A. B. et al. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor. Nat. Chem. Biol. 16, 1105–1110 (2020).
pubmed: 32690941 doi: 10.1038/s41589-020-0589-7
Chen, S. et al. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography. Nat. Commun. 10, 638 (2019).
pubmed: 30733446 pmcid: 6367319 doi: 10.1038/s41467-019-08568-5
Zou, S. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int. J. Mol. Sci. 19, 833 (2018).
pmcid: 5877694 doi: 10.3390/ijms19030833
Lu, D., Immadi, S. S., Wu, Z. & Kendall, D. A. Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. Acta Pharmacol. Sin. 40, 324–335 (2019).
pubmed: 30333554 doi: 10.1038/s41401-018-0164-x
Lane, J. R., May, L. T., Parton, R. G., Sexton, P. M. & Christopoulos, A. A kinetic view of GPCR allostery and biased agonism. Nat. Chem. Biol. 13, 929–937 (2017).
pubmed: 28820879 doi: 10.1038/nchembio.2431
Foster, D. J. & Conn, P. J. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94, 431–446 (2017).
pubmed: 28472649 pmcid: 5482176 doi: 10.1016/j.neuron.2017.03.016
Morales, P., Goya, P., Jagerovic, N. & Hernandez-Folgado, L. Allosteric modulators of the CB1 cannabinoid receptor: a structural update review. Cannabis Cannabinoid Res. 1, 22–30 (2016).
pubmed: 28861476 pmcid: 5576597 doi: 10.1089/can.2015.0005
Shao, Z. et al. Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat. Chem. Biol. 15, 1199–1205 (2019).
pubmed: 31659318 doi: 10.1038/s41589-019-0387-2
Latorraca, N. R., Venkatakrishnan, A. J. & Dror, R. O. GPCR dynamics: structures in motion. Chem. Rev. 117, 139–155 (2017).
pubmed: 27622975 doi: 10.1021/acs.chemrev.6b00177
Ignatowska-Jankowska, B. M. et al. A cannabinoid CB 1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology 40, 2948–2959 (2015).
pubmed: 26052038 pmcid: 4864630 doi: 10.1038/npp.2015.148
Cheng, R. K. Y. et al. Structural insight into allosteric modulation of protease-activated receptor 2. Nature 545, 112–115 (2017).
pubmed: 28445455 doi: 10.1038/nature22309
Srivastava, A. et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124–127 (2014).
pubmed: 25043059 doi: 10.1038/nature13494
Hua, T. et al. Crystal structure of the human cannabinoid receptor CB1. Cell 167, 750–762.e14 (2016).
pubmed: 27768894 pmcid: 5322940 doi: 10.1016/j.cell.2016.10.004
Hua, T. et al. Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures. Cell 180, 655–665.e18 (2020).
pubmed: 32004463 pmcid: 7898353 doi: 10.1016/j.cell.2020.01.008
Zhou, Q. et al. Common activation mechanism of class A GPCRs. eLife 8, e50279 (2019).
pubmed: 31855179 pmcid: 6954041 doi: 10.7554/eLife.50279
Hilger, D. et al. Structural insights into differences in G protein activation by family A and family B GPCRs. Science 369, eaba3373 (2020).
pubmed: 32732395 pmcid: 7954662 doi: 10.1126/science.aba3373
Liu, K. et al. Structural basis of CXC chemokine receptor 2 activation and signalling. Nature 585, 135–140 (2020).
pubmed: 32610344 doi: 10.1038/s41586-020-2492-5
Shao, Z. et al. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature 540, 602–606 (2016).
pubmed: 27851727 pmcid: 5433929 doi: 10.1038/nature20613
Díaz, Ó., Dalton, J. A. & Giraldo, J. Revealing the mechanism of agonist-mediated cannabinoid receptor 1 (CB1) activation and phospholipid-mediated allosteric modulation. J. Med. Chem. 62, 5638–5654 (2019).
pubmed: 31095906 doi: 10.1021/acs.jmedchem.9b00612
Grahl, A., Abiko, L. A., Isogai, S., Sharpe, T. & Grzesiek, S. A high-resolution description of β1-adrenergic receptor functional dynamics and allosteric coupling from backbone NMR. Nat. Commun. 11, 2216 (2020).
pubmed: 32371991 pmcid: 7200737 doi: 10.1038/s41467-020-15864-y
Bonomi, M. & Parrinello, M. Enhanced sampling in the well-tempered ensemble. Phys. Rev. Lett. 104, 190601 (2010).
pubmed: 20866953 doi: 10.1103/PhysRevLett.104.190601
Galdadas, I. et al. Structural basis of the effect of activating mutations on the EGF receptor. eLife 10, e65824 (2021).
pubmed: 34319231 pmcid: 8318590 doi: 10.7554/eLife.65824
Lovera, S. et al. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 134, 2496–2499 (2012).
pubmed: 22280319 doi: 10.1021/ja210751t
Zanetti-Domingues, L. C. et al. The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers. Nat. Commun. 9, 4325 (2018).
pubmed: 30337523 pmcid: 6193980 doi: 10.1038/s41467-018-06632-0
Mattedi, G., Acosta-Gutiérrez, S., Clark, T. & Gervasio, F. L. A combined activation mechanism for the glucagon receptor. Proc. Natl Acad. Sci. USA 117, 15414–15422 (2020).
pubmed: 32571939 pmcid: 7355025 doi: 10.1073/pnas.1921851117
Mattedi, G., Deflorian, F., Mason, J. S., de Graaf, C. & Gervasio, F. L. Understanding ligand binding selectivity in a prototypical GPCR family. J. Chem. Inf. Model. 59, 2830–2836 (2019).
pubmed: 31125224 pmcid: 7007187 doi: 10.1021/acs.jcim.9b00298
Raniolo, S. & Limongelli, V. Ligand binding free-energy calculations with funnel metadynamics. Nat. Protoc. 15, 2837–2866 (2020).
pubmed: 32814837 doi: 10.1038/s41596-020-0342-4
Tiwary, P. & Parrinello, M. A time-independent free energy estimator for metadynamics. J. Phys. Chem. B 119, 736–742 (2015).
pubmed: 25046020 doi: 10.1021/jp504920s
Taylor, B. C., Lee, C. T. & Amaro, R. E. Structural basis for ligand modulation of the CCR2 conformational landscape. Proc. Natl Acad. Sci. USA 116, 8131–8136 (2019).
pubmed: 30975755 pmcid: 6486717 doi: 10.1073/pnas.1814131116
Lu, S. et al. Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design. Nat. Commun. 12, 4721 (2021).
pubmed: 34354057 pmcid: 8342441 doi: 10.1038/s41467-021-25020-9
Kato, H. E. et al. Conformational transitions of a neurotensin receptor 1-Gi1 complex. Nature 572, 80–85 (2019).
pubmed: 31243364 pmcid: 7065593 doi: 10.1038/s41586-019-1337-6
Dror, R. O. et al. Activation mechanism of the β2-adrenergic receptor. Proc. Natl Acad. Sci. USA 108, 18684–18689 (2011).
pubmed: 22031696 pmcid: 3219117 doi: 10.1073/pnas.1110499108
Manglik, A. et al. Structural insights into the dynamic process of β2-adrenergic receptor signaling. Cell 161, 1101–1111 (2015).
pubmed: 25981665 pmcid: 4441853 doi: 10.1016/j.cell.2015.04.043
Bolhuis, P. G. Kinetic pathways of β-hairpin (un)folding in explicit solvent. Biophys. J. 88, 50–61 (2005).
pubmed: 15516524 doi: 10.1529/biophysj.104.048744
Bussi, G., Gervasio, F. L., Laio, A. & Parrinello, M. Free-energy landscape for β hairpin folding from combined parallel tempering and metadynamics. J. Am. Chem. Soc. 128, 13435–13441 (2006).
pubmed: 17031956 doi: 10.1021/ja062463w
Tao, Q. & Abood, M. E. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J. Pharmacol. Exp. Ther. 285, 651 (1998).
pubmed: 9580609
Wingler, L. M. et al. Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. Science 367, 888–892 (2020).
pubmed: 32079768 pmcid: 7171558 doi: 10.1126/science.aay9813
Varma, N. et al. Crystal structure of jumping spider rhodopsin-1 as a light sensitive GPCR. Proc. Natl Acad. Sci. USA 116, 14547 (2019).
pubmed: 31249143 pmcid: 6642406 doi: 10.1073/pnas.1902192116
D’Antona, A. M., Ahn, K. H. & Kendall, D. A. Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry 45, 5606–5617 (2006).
pubmed: 16634642 doi: 10.1021/bi060067k
Lu, J. et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat. Rev. Mol. Cell Biol. 24, 570–577 (2017).
Kruse, A. C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101–106 (2013).
pubmed: 24256733 pmcid: 4020789 doi: 10.1038/nature12735
Maeda, S., Qu, Q., Robertson, M. J., Skiniotis, G. & Kobilka, B. K. Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes. Science 364, 552 (2019).
pubmed: 31073061 pmcid: 7034192 doi: 10.1126/science.aaw5188
Liu, X. et al. Mechanism of β2AR regulation by an intracellular positive allosteric modulator. Science 364, 1283–1287 (2019).
pubmed: 31249059 pmcid: 6705129 doi: 10.1126/science.aaw8981
Lin, S. et al. Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature 594, 583–588 (2021).
pubmed: 34135510 doi: 10.1038/s41586-021-03495-2
Shen, C. et al. Structural basis of GABAB receptor–Gi protein coupling. Nature 594, 594–598 (2021).
pubmed: 33911284 pmcid: 8222003 doi: 10.1038/s41586-021-03507-1
Xiao, P. et al. Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes. Cell 184, 943–956.e18 (2021).
pubmed: 33571432 doi: 10.1016/j.cell.2021.01.028
Qi, X., Friedberg, L., De Bose-Boyd, R., Long, T. & Li, X. Sterols in an intramolecular channel of Smoothened mediate Hedgehog signaling. Nat. Chem. Biol. 16, 1368–1375 (2020).
pubmed: 32929279 pmcid: 7669734 doi: 10.1038/s41589-020-0646-2
Mao, C. et al. Cryo-EM structures of inactive and active GABAB receptor. Cell Res. 30, 564–573 (2020).
pubmed: 32494023 pmcid: 7343782 doi: 10.1038/s41422-020-0350-5
Yan, W. et al. Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode. Nat. Commun. 11, 5287 (2020).
pubmed: 33082324 pmcid: 7576152 doi: 10.1038/s41467-020-19109-w
Collaborative Computational Project, No. 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr . 50, 760–763 (1994).
doi: 10.1107/S0907444994003112
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840 pmcid: 2483472 doi: 10.1107/S0021889807021206
Koehl, A. et al. Structure of the µ-opioid receptor–G
pubmed: 29899455 pmcid: 6317904 doi: 10.1038/s41586-018-0219-7
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466 pmcid: 5494038 doi: 10.1038/nmeth.4193
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
pubmed: 20057044 doi: 10.1107/S0907444909042073
Olsen, R. H. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841–849 (2020).
pubmed: 32367019 pmcid: 7648517 doi: 10.1038/s41589-020-0535-8
Huang, J. & MacKerell, A. D. Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 34, 2135–2145 (2013).
pubmed: 23832629 pmcid: 3800559 doi: 10.1002/jcc.23354
Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19–25 (2015).
doi: 10.1016/j.softx.2015.06.001

Auteurs

Xin Yang (X)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Xuehui Wang (X)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zheng Xu (Z)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Chao Wu (C)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Yangli Zhou (Y)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Yifei Wang (Y)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Guifeng Lin (G)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Kan Li (K)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Ming Wu (M)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Anjie Xia (A)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Jingming Liu (J)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Lin Cheng (L)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Jun Zou (J)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Wei Yan (W)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zhenhua Shao (Z)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. zhenhuashao@scu.edu.cn.
Division of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China. zhenhuashao@scu.edu.cn.

Shengyong Yang (S)

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. yangsy@scu.edu.cn.

Articles similaires

Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
Cryoelectron Microscopy Algorithms Image Processing, Computer-Assisted Consensus Software

Classifications MeSH